Volume 10, Issue 1 (6-2023)                   vacres 2023, 10(1): 1-5 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Zarei M, Zakeri A, Khalili S, Hashemi Z S. SARS-CoV-2 Lambda and Omicron Variants: Antigenicity Evaluation of Spike Proteins as Potential Targets for Vaccine Development. vacres 2023; 10 (1) :1-5
URL: http://vacres.pasteur.ac.ir/article-1-323-en.html
Department of Biology Sciences, Shahid Rajaee Teacher Training University, Tehran, Iran
Abstract:   (1036 Views)
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide as an Omicron variant (B.1.1.529). Compared with the original SARS-CoV-2, this variant has more than 30 mutations on its spike. The Lambda variant (known as SARS-CoV-2 lineage C.37) is another variant of interest. The Lambda spike protein bears seven mutations; G75V, T76I, L452Q, F490S, D614G, T859N, and ∆247-253. The effect of such mutations on immune escape from neutralizing antibodies and infectivity is unknown. Methods: In-silico tools were applied to predict the antigenicity of the spikes of Lambda and Omicron variants and the results were compared to the reference Wuhan spike protein antigenicity. SWISS-MODEL, MolProbity, and QMEAN were used for model quality assessment. DiscoTope2.0, BEpro, and Ellipro were used for the prediction of conformational and linear B cell epitopes. Results: The evaluation of the obtained modeled proteins showed that the predicted models by Swiss-Model had higher quality for Lambda and Omicron spikes with 0.56% and 1.63% of residues in outlier and 94.39% and 92.51% residues in favored regions, respectively. The results of conformational B cell epitope prediction showed 6 epitopic regions on S1 of Lambda spike and 1 epitopic region on the S2 segment of the protein. For the Omicron variant, 9 epitopic regions existed on S1 and 1 epitopic region (1137-1159) was on S2. Conclusion: Our results suggested that B cell epitope removal and reducing the antigenicity properties of the epitopic residues involve reducing susceptibility to antibody neutralization of the mutant protein
Full-Text [PDF 577 kb]   (330 Downloads)    
Type of Study: Research | Subject: Immunologic studies and animal models
Received: 2023/06/16

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Vaccine Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.